Chasing Merck, BioNTech and DualityBio post first clinical data on ADC

Duality Biologics has shared the first data from a phase 1/2a antibody-drug conjugate (ADC) trial, giving an early look at how the BioNTech-partnered asset is shaping up against rival molecules in development at companies including Merck & Co.